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ABSTRACT Bacteria can be motile and planktonic or, alternatively, sessile and partici-
pating in the biofilm mode of growth. The transition between these lifestyles can be
regulated by a second messenger, cyclic dimeric GMP (c-di-GMP). High intracellular c-di-
GMP concentration correlates with biofilm formation and motility inhibition in most bac-
teria, including Bordetella bronchiseptica, which causes respiratory tract infections in
mammals and forms biofilms in infected mice. We previously described the diguanylate
cyclase BdcA as involved in c-di-GMP synthesis and motility regulation in B. bronchisep-
tica; here, we further describe the mechanism whereby BdcA is able to regulate motility
and biofilm formation. Amino acid replacement of GGDEF with GGAAF in BdcA is consis-
tent with the conclusion that diguanylate cyclase activity is necessary for biofilm forma-
tion and motility regulation, although we were unable to confirm the stability of the
mutant protein. In the absence of the bdcA gene, B. bronchiseptica showed enhanced
motility, strengthening the hypothesis that BdcA regulates motility in B. bronchiseptica.
We showed that c-di-GMP-mediated motility inhibition involved regulation of flagellin
expression, as high c-di-GMP levels achieved by expressing BdcA significantly reduced
the level of flagellin protein. We also demonstrated that protein BB2109 is necessary for
BdcA activity, motility inhibition, and biofilm formation. Finally, absence of the bdcA
gene affected bacterial infection, implicating BdcA-regulated functions as important for
bacterium-host interactions. This work supports the role of c-di-GMP in biofilm formation
and motility regulation in B. bronchiseptica, as well as its impact on pathogenesis.
IMPORTANCE Pathogenesis of Bordetella spp., like that of a number of other patho-
gens, involves biofilm formation. Biofilms increase tolerance to biotic and abiotic fac-
tors and are proposed as reservoirs of microbes for transmission to other organs
(trachea, lungs) or other hosts. Bis-(3=-5=)-cyclic dimeric GMP (c-di-GMP) is a second
messenger that regulates transition between biofilm and planktonic lifestyles. In Bor-
detella bronchiseptica, high c-di-GMP levels inhibit motility and favor biofilm forma-
tion. In the present work, we characterized a B. bronchiseptica diguanylate cyclase,
BdcA, which regulates motility and biofilm formation and affects the ability of B.
bronchiseptica to colonize the murine respiratory tract. These results provide us with
a better understanding of how B. bronchiseptica can infect a host.
KEYWORDS biofilm, Bordetella, motility, c-di-GMP
Cyclic dimeric GMP (c-di-GMP) is a ubiquitous second messenger in bacteria thatregulates multiple phenotypes (1, 2). In a multitude of bacteria, c-di-GMP regulates
transitions between a motile, planktonic lifestyle and a sessile, biofilm mode of growth.
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Moreover, in several pathogens, c-di-GMP also influences virulence (2). The intracellular
concentration of c-di-GMP is regulated by diguanylate cyclases (DGCs) and phosphodi-
esterases (PDEs). Enzymes with DGC activity share a domain characterized by the
presence of a GGDEF (or similar) sequence; these enzymes synthesize c-di-GMP from
two molecules of GTP (3). The c-di-GMP-degrading PDE activity is associated with
enzymes that have either EAL or HD-GYP motifs. The c-di-GMP network is complex and
regulates phenotypes through different mechanisms, including gene expression regu-
lation, posttranslational regulation, protein conformation modulation, and protein-
protein interactions (3). Indeed, c-di-GMP can regulate rapid transitions between
lifestyles, thus likely allowing pathogens to adapt quickly to new environments during
transitions between hosts. Recently, we showed that c-di-GMP regulates motility and
biofilm formation in Bordetella bronchiseptica (4). As for other bacteria, high c-di-GMP
levels in B. bronchiseptica correlate with reduced motility and the biofilm-forming
phenotype, suggesting that c-di-GMP signals could affect interactions with the host.
Bordetella bronchiseptica is a Gram-negative bacterium that causes respiratory tract
infections, producing kennel cough in dogs, atrophic rhinitis in pigs, and snuffles in
rabbits (5). The ability of this organism to form biofilms has been previously reported;
the BvgAS two-component system is involved in control of biofilm formation (6, 7).
Most known B. bronchiseptica virulence factors are also regulated by BvgAS (8). To date,
no known signal has been described for the sensor histidine kinase BvgS, but it has
been reported that BvgS is typically active with specific signals inhibiting its function
(9). In vitro signals, such as low temperature, sulfate ions, and nicotinic acid (NA), have
inhibitory effects on BvgS activity (8).
Inactive BvgAS results in the absence of virulence factor expression, resulting in the
so-called “avirulent phase,” thought to be associated with free-living bacteria. When
BvgAS is active, virulence factors are expressed and bacteria are considered to be in the
“virulent phase,” which can infect a naive host (10). Virulent-phase bacteria are non-
motile, and BvgAS is necessary and sufficient to inhibit flagellin expression during the
virulent phase (11). It is also possible to observe an intermediate phenotype, presum-
ably involved in transmission between hosts—the “intermediate phase” (12). Although
the intermediate phase supports the most robust biofilm formation, B. bronchiseptica
can form biofilms in any of the three phases (4). Further, transcriptome analysis has
shown that genes independent of BvgAS regulation are differentially expressed during
biofilm formation compared to those during planktonic culture (13). Thus, further
studies are needed to elucidate all factors affecting biofilm formation, motility, and
interaction with the host.
We previously showed that a putative DGC from B. bronchiseptica, the predicted
gene product of the BB3576 gene, enhances biofilm formation and inhibits motility,
consistent with its predicted DGC activity (4). Here, we confirm that BB3576 regulates
biofilm formation and motility in B. bronchiseptica. We further demonstrate that BB3576
impacts flagellar expression and host infection, likely via its DGC activity, which
suggests that c-di-GMP-mediated regulation is a key player in the pathogenesis of this
organism.
RESULTS
Expression of bdcA (BB3576) increases c-di-GMP levels and reduces motility of
B. bronchiseptica. We have shown previously that overexpression of BB3576, a pre-
dicted DGC of B. bronchiseptica, inhibits swimming motility in soft agar (4). We
proposed that if BB3576 is a functional DGC, motility inhibition might be due to high
c-di-GMP levels produced by this protein. To test this hypothesis, we quantified
intracellular c-di-GMP in B. bronchiseptica with the BB3576 gene expressed from a
plasmid under the control of a strong promoter (pnptII) (Fig. 1A). c-di-GMP levels
normalized by dry weight were ;9 times higher when BB3576 was expressed from the
plasmid rather than the vector control (pEmpty) (Fig. 1A). When the GGDEF domain was
replaced with GGAAF, the measured levels of c-di-GMP were equivalent to levels in the
wild type (WT) carrying the control vector (Fig. 1A). We tried several approaches to
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detect the WT and the mutant variant of the BB3576 protein when expressed from a
plasmid, including using 63His, 33Flag, and streptavidin epitope tags as well as
enriching for the membrane fraction of cell extracts for this predicted inner membrane
protein, but we could not detect the WT or mutant protein. Thus, it is not clear if the
phenotype of the BB3576-GGAAF mutant protein is due to loss of DGC activity or
destabilization of the protein. It is important to note that similar mutations have been
made in many DGCs with no apparent loss of protein stability (14–16). Moreover, only
when intracellular c-di-GMP levels were high was motility reduced in the soft agar
assay (Fig. 1). These results suggest that c-di-GMP produced by BB3576 inhibits
motility; based on these findings, we named BB3576 the Bordetella diguanylate
cyclase A (bdcA).
We previously showed that overexpression of bdcA induced a significant increase in
biofilm levels (4), which is consistent with the high intracellular c-di-GMP levels ob-
served here for the strain expressing this gene from a plasmid (Fig. 1A). As previously
reported, expression of bdcA enhanced biofilm formation, modulating bacteria with
either nicotinic acid or MgSO4 (Fig. 2A; see also Fig. S1 in the supplemental material).
The biomass detected by crystal violet (CV) assay includes live and dead cells, lysed
cells, and other CV staining matrix components like polysaccharides and extracellular
DNA (eDNA) that may lead to the observed increased values. Thus, we also analyzed the
biofilm by scanning electron microscopy (SEM). B. bronchiseptica expressing bdcA from
a plasmid showed larger three-dimensional (3D) structures than wild-type B. bron-
chiseptica in all conditions analyzed by SEM (Fig. 2C). Hence, we confirmed that the
observed differences are a consequence of more bacteria forming a biofilm rather than
simply increased production of matrix components.
Biofilm enhancement was not observed in bacteria carrying the empty vector or
expressing the bdcA-GAAF variant, suggesting that c-di-GMP production is required for
the enhanced biofilm formation observed when bdcA is overexpressed. We also deleted
the bdcA gene in B. bronchiseptica Bb9.73 and evaluated biofilm formation by the
BbΔbdcA mutant compared with that of the wild-type strain at virulent, intermediate,
and avirulent phases. There was no statistically significant reduction in biofilm forma-
tion for any nicotinic acid concentration tested for the BbΔbdcA mutant versus that of
the WT control (Fig. 2B).
B. bronchiseptica and Bordetella pertussis can form biofilm-like structures on nasal
epithelial cells in vivo (17). Although the ΔbdcA deletion mutant did not affect biofilm
formation on the abiotic surface tested here, we evaluated biofilm formation on a biotic
FIG 1 Expression of the bdcA (BB3576) gene from a plasmid increases c-di-GMP levels and reduces motility of B.
bronchiseptica. (A) Quantitative measurements of cellular c-di-GMP concentration from strains carrying the
Bb-pEmpty, Bb-pbdcA, and Bb-pbdcA(GAAF) plasmids. (B) Swimming motility using a soft agar (0.35%) motility
assay with the B. bronchiseptica strains described for panel A. Diameters greater than 4 mm were indicative of
motility. Means with standard errors are shown. Means marked with an asterisk are significantly different from
those for Bb-pEmpty (Tukey, P , 0.001).
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surface—a cystic fibrosis bronchial epithelial cell line—as described previously (18). In
concordance with the abiotic surface experiments, we observed no significant differ-
ence in viable biofilm cells recovered for wild-type B. bronchiseptica Bb9.73 or the
ΔbdcA derivative at 6, 10, and 24 h postinoculation (see Fig. S2 in the supplemental
material).
c-di-GMP inhibits flagellin production by B. bronchiseptica. Motility regulation
by c-di-GMP has been described in numerous bacteria (19), and we have observed a
similar finding for B. bronchiseptica in Fig. 1B. One mechanism of motility control by
c-di-GMP is regulation of flagellum production. We performed Western blot analysis to
determinate if c-di-GMP can inhibit flagellin protein production. In these experiments,
we used wild-type B. bronchiseptica Bb9.73, as well as a bvgA mutant strain (Bb-bvgA
mutant), which is known to regulate expression of the flagellar protein as a control.
Wild-type B. bronchiseptica produced the flagellin protein only when grown in the
presence of MgSO4 (40 mM), which is known to regulate BvgAS activity (Fig. 3A, first
and second panels; see also Fig. S1). However, when bdcA was expressed from a
plasmid and c-di-GMP levels were high (Fig. 1), flagellin production was repressed (Fig.
3A, second panel). As expected, when the bvgA gene was disrupted, flagellin was
produced independently of MgSO4 addition to culture medium (Fig. 3A, first lanes of
FIG 2 Biofilm formation assay. (A, B) Biofilm formation by the indicated B. bronchiseptica strains grown in SS
medium either alone or supplemented with nicotinic acid (NA) at the indicated concentration. Biofilm formation
was assessed by crystal violet (CV) staining after 24 h in static incubation conditions. Results are based on three
biologically independent replicates, and means with standard errors are shown. Means marked with an asterisk are
significantly different from those for Bb-pEmpty in the same NA concentration (Tukey, P , 0.01). (C) Scanning
electron microscope images of B. bronchiseptica biofilms. Bb-pEmpty (left) and Bb-pbdcA (right) were grown
statically on vertically submerged coverslips at the indicated nicotinic acid concentration. After 24 h of growth, the
biofilms formed at the air-liquid interface were visualized. We performed two independent experiments and
examined ;20 fields per sample; a representative image is shown.
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third and fourth panels). Interestingly, the presence of flagellin in the bvgA mutant
background was drastically diminished when bdcA was expressed from plasmid but
only in the absence of MgSO4 (Fig. 3A, third panel). We repeated the Western blot with
a bvgS deletion mutant (RB54); the flagellin expression pattern phenocopied the bvgA
mutant (see Fig. S3A in the supplemental material). Together, these data suggest that
MgSO4 may be enhancing flagellar gene expression independently of the BvgAS
system and/or c-di-GMP. These data are also consistent with the model that increased
c-di-GMP reduces motility at least in part via reduction in the level of flagella.
Finally, motility in soft agar assay was observed when flagellin production was
detected (Fig. 3B). In the Bb-bvgA mutant grown in 40 mM MgSO4, despite relatively
high levels of flagellin, the strain showed lower motility when BdcA was overexpressed
(Fig. 3B, far right bars). This was also observed in the B. bronchiseptica RB54 background
(Fig. S3B). These data are consistent with findings from other organisms that c-di-GMP-
mediated regulation can impact both flagellar gene expression and flagellar function
(19).
To assess whether the change in flagellar protein levels might be due to changes in
flaA gene expression, we transformed B. bronchiseptica with an flaA promoter-gfp
transcriptional fusion introduced onto the genome. The fluorescence of the wild-type
strain was significantly higher when bacteria were grown with MgSO4 (40 mM) com-
pared to medium only (Fig. S4). In agreement with motility and Western blot results,
expression of the bdcA gene from a plasmid resulted in a modest but significant
reduction in fluorescence from the flaA-gfp transcriptional fusion (see Fig. S4 in the
supplemental material).
FIG 3 c-di-GMP inhibits flagellin production in B. bronchiseptica. (A) Western blot with polyclonal anti-FlaA antibody
was used to detect FlaA of B. bronchiseptica for each indicated strain grown either in the absence or presence of
40 mM MgSO4. (B) Motility phenotypes of B. bronchiseptica strains used in Western blot analysis in panel A.
Diameters greater than 4 mm were indicative of motility. Means with standard errors are shown. Means marked
with an asterisk are significantly different from those for the same strain harboring the pEmpty plasmid in the same
medium (Tukey, P , 0.01).
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BdcA reduces motility in the soft agar assay. Given that c-di-GMP apparently
regulates motility, we wondered if BdcA has a physiological role in generating c-di-
GMP. We hypothesized that if BdcA inhibits motility, deletion of the bdcA gene would
trigger an increased motility phenotype. As predicted, the strain with a bdcA deletion
showed a significantly higher zone of motility (increased by 31%) in the soft agar assay
(Fig. 4A). Our results support the idea that BdcA is involved in producing c-di-GMP
levels contributing to the inhibition of motility by B. bronchiseptica in the avirulent
phase (i.e., in the presence of MgSO4). Accordingly, intracellular c-di-GMP concentration
in the BbΔbdcA mutants was significantly lower than wild-type levels of this second
messenger (Fig. 4B). Thus, while loss of the bdcA gene did not significantly reduce
biofilm formation, it did show enhanced motility.
The YcgR homolog of B. bronchiseptica plays no apparent role in motility
regulation in our assay conditions. The c-di-GMP binding proteins are responsible for
signal transduction pathways responsive to c-di-GMP. Given that c-di-GMP regulates
biofilm formation and motility in B. bronchiseptica, we predicted that one or more
c-di-GMP binding proteins participate in this regulation. One class of c-di-GMP receptor
in bacteria is proteins with PilZ domains. The B. bronchiseptica genome harbors only
one gene encoding a protein with a PilZ domain, ycgR. YcgR of B. bronchiseptica is a
predicted homologue of the YcgR protein of Escherichia coli, a reported PilZ domain
protein important for regulation of flagellar function (20–22); YcgR of B. bronchiseptica
and YcgR of E. coli share 22% sequence identity and 42% similarity at the amino acid
level. We generated a clean deletion of the ycgR gene and expressed bdcA from a
plasmid in this mutant background to establish if c-di-GMP produced by BdcA is sensed
by YcgR. The ycgR mutant showed no change in motility in the soft agar assay
compared to the WT in these experimental conditions (Fig. 5A, first columns). If YcgR
is necessary to inhibit motility when bdcA is expressed from a plasmid, absence of YcgR
would abolish the BdcA-mediated inhibition of motility. As shown in Fig. 5A, motility in
soft agar was inhibited by BdcA even in the absence of YcgR.
c-di-GMP motility inhibition and biofilm regulation are not dependent on the
LapD homolog of B. bronchiseptica. We previously described a LapD homolog of B.
bronchiseptica (23). LapD is a c-di-GMP receptor protein that controls the cell surface
localization of BrtA, a large adhesin required for biofilm formation (23). We speculated
that LapD may sense c-di-GMP produced by BdcA to regulate motility. The B. bron-
chiseptica ΔlapD mutant had no significant effect on motility in the soft agar assay (Fig.
5A). We also expressed bdcA in the B. bronchiseptica ΔlapD mutant background and
FIG 4 BdcA regulates motility by modifying c-di-GMP levels. (A) Motility phenotype of B. bronchiseptica
9.73 and the BbΔbdcA strains in SS motility agar, as described in Materials and Methods. Means with
standard errors are shown. The mean marked with an asterisk is significantly different from that for
wild-type B. bronchiseptica Bb9.73 (Tukey, P , 0.01). (B) Quantitative measurement of cellular c-di-GMP
level of B. bronchiseptica Bb9.73 and the BbΔbdcA mutant. Formic acid-extracted c-di-GMP was measured
by liquid chromatography-mass spectrometry and normalized to milligrams dry weight of bacteria after
extraction. Means with standard errors are shown. The mean marked with an asterisk is significantly
different from that for Bb-pEmpty (Tukey, P , 0.001).
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performed motility experiments. As shown in Fig. 5A, expression of the bdcA gene from
a plasmid could inhibit motility even in the absence of the LapD homolog. Together,
these data indicate no role for the LapD homolog of B. bronchiseptica in motility as
assessed in the soft agar assay.
c-di-GMP motility inhibition and biofilm regulation are dependent on BB2109.
Dahlstrom and coworkers postulated that some DGCs interact with EAL domains
through particular protein surfaces they called “bar codes and readers” (24). These
investigators were able to predict the interaction of proteins from Pseudomonas
aeruginosa by comparing modeled structures of DGCs and EAL domains. We modeled
BdcA and every EAL domain-containing protein encoded by the B. bronchiseptica RB50
genome with Phyre2 software (25) and searched for bar code/reader matching pairs for
the BdcA protein. We found that the predicted a2 helix of the EAL domain of BB2109,
a membrane protein that also contains the GGDEF domain, is a plausible match with
the a5 helix of the DGC domain of BdcA based on complementary charge-charge
interactions (Fig. 5B). The BB2109 protein also harbors another predicted domain (BaeS)
usually present in histidine kinases. Individual alignment of either EAL or GDDEF
domains suggested the absence of PDE or DGC activity for BB2109 based on a lack of
key residues in the predicted active sites (Fig. 5C; see also the supplemental material).
To test whether BB2109 impacts motility, we constructed a deletion of the BB2109
gene. The ΔBB2109 mutant resulted in a small, but not significant, reduction in motility
(Fig. 5A, rightmost black column). To evaluate whether the BB2109 protein is needed
FIG 5 BB2109 is required for c-di-GMP-mediated motility inhibition. (A) Motility phenotypes of B. bronchiseptica Bb9.73 and the BbΔycgR, BbΔlapD, and
BbΔBB2109 mutants carrying pEmpty, pbdcA, or pbdcB plasmids on SS motility agar as described in Materials and Methods. Means with standard errors are
shown. Means marked with an asterisk are significantly different from those for the same strain harboring the pEmpty plasmid (Tukey, P , 0.001). (B) The regions
of BdcA and BB2109 that may interact with each other are shown in this ribbon diagram. Five surface residues that are possible points of contact are shown
in a5 BdcA and a2 BB2109 helixes. (C) Conservation of residues in EAL and GGDEF domains of BB2109. The residues that form the enzyme active sites and are
required for diguanylate cyclase activity are shown in red. In the EAL domain, the catalytic EAL domain is shown in red. Green indicates amino acids involved
in Mg21 binding; blue indicates amino acids involved in substrate binding; orange indicates glutamate-stabilizing loop 6. Colors are as used by Römling et al.
(31). For more details, see the supplemental material.
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for BdcA-mediated motility inhibition in B. bronchiseptica, we assessed this phenotype
both when bdcA is expressed from a plasmid and in a BbΔBB2109 mutant background.
In the mutant, BdcA was unable to inhibit motility, indicating that this protein is needed
for motility inhibition under these conditions (Fig. 5A). To determine if the combined
role of BB2109 and BdcA in motility inhibition was specific, we analyzed another
predicted B. bronchiseptica DGC, BdcB. Expression of bdcB from a plasmid inhibited
motility either in the presence or absence of BB2109 (Fig. 5A, rightmost white bar),
indicating that BB2109 is involved specifically in BdcA-mediated motility inhibition.
We also checked whether the protein BB2109 was necessary for biofilm formation
when bdcA was expressed from a plasmid. As shown in Fig. 6, biofilm formation in the
strain carrying the bdcA-expressing plasmid was only observed in the presence of
BB2109. Dependence on the presence of BB2109 was observed in all nicotinic acid (Fig.
6) or MgSO4 concentrations (not shown) where BdcA stimulated biofilm formation.
These results indicated that BB2109 and BdcA may work together to generate c-di-GMP,
a hypothesis we test below.
BdcA-mediated c-di-GMP production is BB2109 dependent. Motility inhibition
and enhancement of biofilm formation by BdcA were BB2109 dependent. The BB2109
protein may be either a receptor for c-di-GMP synthesized by BdcA or necessary for
proper function of BdcA as a DGC. In the first proposed mechanism, we would expect
to observe high c-di-GMP levels when BdcA was expressed from a plasmid indepen-
dently of a functional BB2109 protein. In contrast, the increased c-di-GMP level would
be dependent on BB2109 if this protein were necessary for BdcA function. To distin-
guish between these possibilities, we quantified c-di-GMP level when bdcA was ex-
pressed from a plasmid in the wild-type and ΔBB2109 mutant backgrounds. We observed
that enhanced c-di-GMP levels in a strain expressing the bdcA gene depended on the
presence of the BB2109 protein (Fig. 7), supporting the hypothesis that BB2109 may
stimulate BdcA activity.
BdcA is necessary to effectively establish a respiratory tract infection in the
murine model. In many pathogens, the c-di-GMP network has been linked to the
ability of bacteria to efficiently colonize a host (26). The deletion of bdcA resulted in
modified intracellular c-di-GMP levels, suggesting that BbΔbdcA may less effectively
colonize the murine respiratory tract. To test this hypothesis, two groups of mice were
intranasally challenged with 5 ml of phosphate-buffered saline (PBS) containing a
variable number (between 6 and 100 CFU) of wild-type or mutant bacteria. Our results
show that the wild-type bacteria could efficiently colonize nasal cavity, trachea, and
lungs with a low inoculum of 12 to 25 CFU. However, the mutant strain required higher
numbers of CFU (50 to 100 CFU) to colonize mice, and those mice had lower overall
FIG 6 BB2109 is required for c-di-GMP-mediated biofilm formation. Biofilm formation by B. bronchiseptica
strains grown in SS medium either alone or supplemented with nicotinic acid (NA) at the indicated
concentration. Biofilm formation was assessed by crystal violet (CV) staining after 24 h in static incubation
conditions. Means with standard errors are shown. Means marked with asterisks are significantly different
(Tukey; *, P , 0.01; **, P , 0.001).
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bacterial numbers recovered from their respiratory tracts 7 days later (Fig. 8). These
differences were observed despite the bdcA mutant having no apparent defect on
growth in vitro (not shown). Overall, these results indicate that the BbΔbdcA strain
colonizes mice less efficiently than wild-type bacteria.
DISCUSSION
In this work, we examined the role of BdcA, a diguanylate cyclase of B. bronchisep-
tica. BdcA is a predicted inner membrane protein of 540 amino acids with two domains,
an N-terminal CACHE (calcium channels and chemotaxis receptor) domain and a
C-terminal GGDEF. This CACHE domain has been described as a sensor domain that
may bind small ligands (27). In previous work, we showed that BdcA inhibits motility
and enhances biofilm formation (4); here, we supported the idea that BdcA is an active
DGC by showing that intracellular levels of c-di-GMP were enhanced by bdcA expres-
sion. While we assume that the GGDEF domain of BdcA is responsible for c-di-GMP
synthesis, the inability to detect the mutant protein by Western blotting limits our
ability to make a solid conclusion.
The physiological role of BdcA was evaluated by deleting this gene in B. bronchisep-
FIG 7 BdcA activity is BB2109 dependent. Quantitative measurement of cellular c-di-GMP level of B.
bronchiseptica Bb9.73 and the BbΔBB2109 mutant carrying the pEmpty or pbdcA plasmids, as indicated.
Means with standard errors are shown. The mean marked with an asterisk is significantly different from
that for Bb-pEmpty (Tukey, P , 0.001).
FIG 8 BdcA is required to effectively establish a respiratory tract infection in a mouse model. Five-week-old mice were intranasally
inoculated with 5 ml of PBS containing bacteria at different bacterial load (6, 12, 25, 50, 100 CFU). Seven days postinoculation,
bacterial loads in the organs of the respiratory tract were enumerated. Each symbol represents a single animal, with the mean
colonization depicted as short horizontal bars. Data are pooled from 2 separate experiments conducted independently. Means
marked with an asterisk are significantly different (Tukey, P , 0.05). Note that some points were allowed to be superimposed when
plotted to increase the clarity of the presentation, but all data were included in the statistical analysis.
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tica. Deletion of bdcA resulted in lower c-di-GMP levels in B. bronchiseptica, supporting
the idea that BdcA is an active DGC; however, we observed no difference in biofilm
formation between WT and the bdcA mutant strain on an abiotic surface or on airway
cells. Although it is well established that c-di-GMP synthesized by DGCs enhances
biofilm formation, absence of a single DGC is usually not enough to impact formation
of biofilms. For example, in Pseudomonas fluorescens, deletion of four DGCs was needed
to abolish biofilm formation in standard laboratory assay conditions (28). Alternatively,
deletion of a single DGC can be important for biofilm formation depending on the
carbon source used (29), indicating that BdcA might participate in biofilm formation in
other environments.
The finding that the loss of the bdcA gene increased motility supports the hypoth-
esis that bdcA regulates motility in B. bronchiseptica, but the deletion of bdcA increases
motility only by 31%, indicating that there may be other DGCs involved in motility
regulation in this microbe. In previous work, we described that bdcA is predominantly
transcribed in the avirulent phase, when this organism is motile (4). It is intriguing that
B. bronchiseptica triggers this apparent inhibitory mechanism during its motile phase.
One report has indicated transient expression of flagellin in the virulent phase (13), and
transcriptome analysis of B. pertussis has also shown discrepancies between virulent
repressed genes and flagellar gene regulation (30). Expression of a negative regulator
of motility during the motile phase of this organism may explain these disparate observa-
tions.
Motility, and particularly flagellin expression, is repressed by the active two-comp-
onent system BvgAS. Here, we determined that overexpression of BdcA can inhibit
motility even when functional BvgA or BvgS is absent. These data suggest that high
c-di-GMP levels can reduce motility even when the organism is in a stage wherein
BvgAS is inactive. However, when MgSO4 was added to medium, c-di-GMP inhibition of
flagellin production was dependent on BvgA or BvgS, suggesting a complex interaction
among c-di-GMP signaling, the BvgAS system, and the regulatory effects of MgSO4.
Importantly, there are conditions wherein flagellin is produced but the cells are less
motile, indicating that c-di-GMP can inhibit motility by one or more other mechanisms.
We demonstrated that homologs of a PilZ domain protein and of LapD, known
c-di-GMP receptors, did not participate in the BdcA-dependent regulation of motility.
Instead, using an approach reported by Dahlstrom and coworkers (24), we were able to
predict a possible interacting partner to BdcA-BB2109, which appears to lack functional
DGC or PDE domains due to the absence of critical catalytic residues. Some such
nonfunctional proteins have been described as c-di-GMP binding proteins (31). Over-
expression of bdcA in the WT background results in almost complete loss of motility
and increased c-di-GMP production; this loss of motility and enhanced c-di-GMP
production are BB2109 dependent. These data suggest that the DGC BdcA and the
putative c-di-GMP receptor BB2109 likely participate in a common pathway to regulate
biofilm formation and motility.
Finally, we noted a connection between c-di-GMP and virulence, illuminating for
the first time that an airborne pathogen like B. bronchiseptica requires a functional
c-di-GMP network to efficiently infect a natural host like the mouse. Interestingly,
dosages of above 50 CFU are necessary for the mutant strain to be able to colonize
the murine respiratory tract, suggesting that high c-di-GMP levels might be re-
quired in the initial steps of infection. Thus, it is plausible that c-di-GMP participates
in regulating adaptation to hosts or to tissues of the same host. Unwrapping the
c-di-GMP network in Bordetella may give us a better understanding of how this
organism infects hosts.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Strains and plasmids used in this study are listed in Table
S1 in the supplemental material. Wild-type B. bronchiseptica 9.73H1 was isolated from a rabbit and
described previously (32). B. bronchiseptica wild-type isolates and mutants were grown on Bordet-
Gengou agar (BGA) (Difco) supplemented with 15% (vol/vol) defibrinated fresh sheep blood (BGA
medium) at 37°C for 48 h and replated in the same medium for 24 h. Stainer-Scholte (SS) liquid medium
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was used to grow B. bronchiseptica in broth cultures (33). When appropriate, BGA or SS was supple-
mented with streptomycin (200 mg ml21), kanamycin (80 mg ml21), and/or gentamicin (50 mg ml21).
Escherichia coli (DH5a, BTH101, and S17-1) strains were cultured with lysogeny broth (LB) (34) in a test
tube or on solidified LB with 1.5% agar. When appropriate, antibiotics were added to the medium at the
following concentrations: 10 mg ml21 gentamicin and 50 mg ml21 kanamycin.
Plasmid and strain construction. Plasmids and strains were constructed using standard molecular
biology techniques; detailed descriptions of construction procedures are in the supplemental material.
Oligonucleotides used in this study are listed in Table S2 in the supplemental material.
Biofilm formation assays. B. bronchiseptica biofilm assays were performed as previously described
by our group (23) from colonies grown in SS semisolid medium (1.5% agar) supplemented with 15%
(vol/vol) defibrinated fresh sheep blood. Bacteria were resuspended in SS medium and pipetted into
wells of a sterile 96-well U-bottom microtiter plate (polyvinylchloride [PVC]). Nicotinic acid or MgSO4
were added at the indicated concentrations when appropriate. After 24 h, attached cells were
stained with crystal violet (CV) solution. The stain was dissolved by adding 33% (vol/vol) acetic acid
solution and then quantified by measuring optical density (OD) at 595 nm. Experiments were
repeated at least three times with at least six technical replicates.
Scanning electron microscopy. B. bronchiseptica biofilm assays for scanning electron microscopy
were performed as previously described by our group (23). Briefly, glass coverslips were vertically
submerged in plastic tubes containing bacteria adjusted to an optical density at 650 nm (OD650) of 0.1.
After 24 h, the coverslip was removed and treated to perform a critical-point procedure using liquid CO2
(EmiTech K850) and sputter coated with gold. Samples were visualized with a scanning electron microscope
(Philips SEM 505), and the images were processed using an image soft imaging system ADDA II.
SDS-PAGE and Western blot analysis. B. bronchiseptica strains were grown at 37°C for 16 h in SS
medium plus gentamicin, with or without MgSO4 (40 mM) as indicated. Cells were collected, normalized
to an equal OD650 value, harvested by boiling samples in 13 Laemmli buffer for 10 min, and subjected
to SDS-polyacrylamide gel electrophoresis followed by transfer of the contents of the gel to a polyvi-
nylidene fluoride (PVDF) filter. After transfer, the PVDF membrane was blocked with 5% nonfat milk
powder in Tris-buffered saline (TBS) for 1 h followed by incubation with polyclonal anti-FlaA serum
diluted 1:2,000 in TBS containing 5% nonfat milk powder at 4°C overnight (35). The filter was then
incubated with anti-mouse IgG conjugated to horseradish peroxidase (HRP) (1:5,000) (Invitrogen) in TBS
containing 5% nonfat milk powder at room temperature for 2.5 h. Horseradish peroxidase-conjugated
anti-mouse antibody (Bio-Rad, USA) was used as the secondary antibody. Chemiluminescent reagent was
used for developing according to manufacturer’s instructions. Samples from each strain and growth
condition combination were prepared and analyzed independently three times.
Measurement of c-di-GMP levels. The c-di-GMP levels were analyzed via liquid chromatography-
mass spectrometry (LC-MS) as previously described (4). Strains were grown in SS liquid medium for 14 h.
Four replicates of each strain were analyzed via LC-MS using the LC-20AD high-performance LC system
(Shimadzu, Columbia, MD) coupled to a Finnigan TSQ Quantum Discovery Max triple-quadrupole mass
spectrometer (Thermo Electron Corp., San Jose, CA). Results are means of three independent experi-
ments.
Motility assays. SS soft agar motility plate (0.35% agar) supplemented with 40 mM MgSO4 and
1.0 mM CaCl2 was used to determine the motility of bacterial strains as previously described (35). We
found that adding 1.0 mM CaCl2 to motility medium allowed better visualization of the migration zone
border. The diameter of the migration zone was measured after 18 h of incubation at 37°C. Experiments
were repeated at least three times with at least three technical replicates.
Fifty percent infective dose. Wild-type C57BL/6J mice were purchased from Jackson Laboratories
(Bar Harbor, ME). Power-G was used to calculate the number of mice needed to obtain statistical
significance (assuming an effect size of 0.60, a power level of 0.80, and a probability level for statistical
significance of 0.05). Briefly, following anesthesia with 5% isoflurane, groups of 7 mice were intranasally
inoculated with 5 ml of PBS containing 6 to 100 CFU of wild-type or mutant B. bronchiseptica. Seven days
postinoculation, mice were euthanized with CO2 followed by cervical dislocation, and organs were
collected in 1 ml of PBS and homogenized using a bead tissue disruptor (Bead Mill 24; Fisher Scientific).
Bacterial load was enumerated by dilution plating; the limit of detection was 10 CFU. Results were
graphed in GraphPad Prism (v8), and statistical significance was calculated using one-way analysis of
variance (ANOVA).
Ethics statement. This study was carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, USA. The protocols
used in this study have been approved by the Institutional Animal Care and Use Committee at the
University of Georgia, Athens, GA (animal usage protocol:A2016 02-010-Y2-A3 Bordetella-Host). Animals
were handled following institutional guidelines, in keeping with full accreditation from the Association
for Assessment and Accreditation of Laboratory Animal Care International.
Statistical analyses. Means were analyzed for significance using a one-way ANOVA with a Tukey’s
multiple-comparison test to compare differences among groups. Shapiro-Wilks test was performed to
confirm normal distribution of data. Significance level is stated in each figure legend.
GenBank accession number. The GenBank accession number for the B. bronchiseptica RB50 genome
is NC_002927.3. Gene identification numbers and locus tags, respectively, for all genes mentioned are as
follows: ycgR, 2663780 and BB_RS07780; bdcA, 2661253 and BB_RS17940; BB2109, 2659958 and
BB_RS10615; bdcB, 2661408 and BB_RS19575; lapD, 2662323 and BB_RS05885.
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